Henan Newland Pharmaceutical Co. Ltd. A
Newland Pharmaceutical Co., Ltd. engages in the research and development, production, and sale of pharmaceutical intermediates and APIs in China. It provides pharmaceutical intermediates, including L-4-hydroxyphenylglycine methyl ester, L-hydroxyphenylglycine potassium salt, L-4-hydroxyphenylglycine, and p-Toluenesulfonic acid. The company also offers APIs, such as ropivacaine hydrochloride, naph… Read more
Henan Newland Pharmaceutical Co. Ltd. A (301277) - Total Assets
Latest total assets as of June 2025: CN¥1.77 Billion CNY
Based on the latest financial reports, Henan Newland Pharmaceutical Co. Ltd. A (301277) holds total assets worth CN¥1.77 Billion CNY as of June 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Henan Newland Pharmaceutical Co. Ltd. A - Total Assets Trend (2020–2024)
This chart illustrates how Henan Newland Pharmaceutical Co. Ltd. A’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Henan Newland Pharmaceutical Co. Ltd. A - Asset Composition Analysis
Current Asset Composition (December 2024)
Henan Newland Pharmaceutical Co. Ltd. A's total assets of CN¥1.77 Billion consist of 65.9% current assets and 34.1% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 15.5% |
| Accounts Receivable | CN¥149.60 Million | 8.3% |
| Inventory | CN¥45.06 Million | 2.5% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥36.82 Million | 2.0% |
| Goodwill | CN¥0.00 | 0.0% |
Asset Composition Trend (2020–2024)
This chart illustrates how Henan Newland Pharmaceutical Co. Ltd. A's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Henan Newland Pharmaceutical Co. Ltd. A's current assets represent 65.9% of total assets in 2024, an increase from 51.4% in 2020.
- Cash Position: Cash and equivalents constituted 15.5% of total assets in 2024, up from 7.0% in 2020.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 2.0% of total assets, a decrease from 7.0% in 2020.
- Asset Diversification: The largest asset category is accounts receivable at 8.3% of total assets.
Henan Newland Pharmaceutical Co. Ltd. A Competitors by Total Assets
Key competitors of Henan Newland Pharmaceutical Co. Ltd. A based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
PINK:BIOVF
|
USA | $67.26 Billion |
|
Kamada
NASDAQ:KMDA
|
USA | $378.79 Million |
|
One World Pharma Inc
OTCQB:OWPC
|
USA | $6.62 Million |
|
Dongwha Pharm.Co.Ltd
KO:000020
|
Korea | ₩654.63 Billion |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078
|
China | CN¥27.28 Billion |
|
Yuhan Corp.
KO:000100
|
Korea | ₩3.05 Trillion |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153
|
China | CN¥4.97 Billion |
|
Kotra Industries Bhd
KLSE:0002
|
Malaysia | RM363.90 Million |
Henan Newland Pharmaceutical Co. Ltd. A - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Henan Newland Pharmaceutical Co. Ltd. A generates 0.40x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Solid ROA - For every $100 in assets, Henan Newland Pharmaceutical Co. Ltd. A generates $9.57 in net profit.
Henan Newland Pharmaceutical Co. Ltd. A - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 5.29 | 5.69 | 7.84 |
| Quick Ratio | 4.95 | 5.54 | 7.66 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥856.55 Million | CN¥ 994.49 Million | CN¥ 1.05 Billion |
Henan Newland Pharmaceutical Co. Ltd. A - Advanced Valuation Insights
This section examines the relationship between Henan Newland Pharmaceutical Co. Ltd. A's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.21 |
| Latest Market Cap to Assets Ratio | 0.09 |
| Asset Growth Rate (YoY) | 12.7% |
| Total Assets | CN¥1.81 Billion |
| Market Capitalization | $164.81 Million USD |
Valuation Analysis
Below Book Valuation: The market values Henan Newland Pharmaceutical Co. Ltd. A's assets below their book value (0.09 x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Henan Newland Pharmaceutical Co. Ltd. A's assets grew by 12.7% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Henan Newland Pharmaceutical Co. Ltd. A (2020–2024)
The table below shows the annual total assets of Henan Newland Pharmaceutical Co. Ltd. A from 2020 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥1.81 Billion | +12.69% |
| 2023-12-31 | CN¥1.61 Billion | +4.94% |
| 2022-12-31 | CN¥1.53 Billion | +129.64% |
| 2021-12-31 | CN¥667.90 Million | +27.96% |
| 2020-12-31 | CN¥521.96 Million | -- |